Children with moderate to severe inflammatory bowel disease (IBD) are treated with systemic glucocorticoids (GCs). The majority of the patients respond to the given treatment; however, steroid resistance and dependency are significant clinical problems. Also therapy-related side effects limit the use of GCs in the control of active inflammation. This review summarizes recent knowledge of GC treatment in pediatric patients with IBD.
机构:
Univ Ulsan, Childrens Hosp, Asan Med Ctr, Coll Med,Dept Pediat, Seoul, South KoreaUniv Ulsan, Childrens Hosp, Asan Med Ctr, Coll Med,Dept Pediat, Seoul, South Korea
机构:
Cedars Sinai Med Ctr, Pediat Inflammatory Bowel Dis Ctr, Dept Pediat, Los Angeles, CA 90048 USACedars Sinai Med Ctr, Pediat Inflammatory Bowel Dis Ctr, Dept Pediat, Los Angeles, CA 90048 USA
Rabizadeh, Shervin
Dubinsky, Marla
论文数: 0引用数: 0
h-index: 0
机构:
Cedars Sinai Med Ctr, Pediat Inflammatory Bowel Dis Ctr, Dept Pediat, Los Angeles, CA 90048 USACedars Sinai Med Ctr, Pediat Inflammatory Bowel Dis Ctr, Dept Pediat, Los Angeles, CA 90048 USA